The current COVID-19 pandemic has brought about countless patients visiting medical care facilities consistently. Due to the COVID-19 flare-up, the quantity of pathological tests conducted globally has diminished. Also, the lockdowns and limitations carried out internationally have contrarily influenced the interest in these solutions in 2020. However, the FDA endorsement for the utilization of advanced pathology solutions for primary diagnostic purposes is relied upon to expand the interest during the forecast period. Hence, the requirement for better remote access to assess the patient's diagnostic tests is expected to build the interest for digital pathology solutions in the coming five years.
The worldwide digital pathology market is projected to arrive at USD 1,054 million by 2025 from USD 553 million every 2020, at a CAGR of 13.8% during the forecast period. The development of this market is significantly attributed to the expanding reception of digital pathology to upgrade lab productivity, the rising predominance of disease, and the developing utilization of advanced pathology in drug improvement and companion diagnostics. However, an absence of trained pathologists is expected to challenge market development in the coming years.
In addition, advancements like microarrays and the incorporation of a wide scope of predictive models, for example, hybrid models and API algorithms are expected to fuel interest for digital image analysis. A rising inclination for computer-aided diagnosis that integrates image processing, physical, mathematics, and computing algorithms, facilitates efficient disease detection and assesses anatomic structures of interest and evaluation of infection progression as well as risk assessment. These advantages are relied upon to fuel the interest in digital pathology framework shortly.
Digital pathology further develops lab effectiveness by diminishing expenses, decreasing turnaround times, and providing users with access to subject-matter expertise. Enhancements in lab efficiency are basic as patients and doctors are subject to lab results for diagnostic decisions, and diagnostic tests are needed to be completed, reported quickly and precisely. Additionally, admittance to digital slides using web services eliminates transportation expenses and pathologists' travel time.
The Digi path organizations, for example, Olympus, Phillips, and Leica are offering a wide scope of tools for remote slide sharing and image processing which is expected to expand the reception throughout the next few years. In April 2020, Leica Biosystems got US FDA endorsement for Aperio AT2 DX Scanner and Aperio WebViewer for remote diagnosis during the pandemic. Additionally, Phillips likewise got USFDA clearance for its IntelliSite Pathology Solution for remote diagnosis during this emergency.
The other key member Koninklijke Philips N.V. in September 2020, helped 100% digitization of histology slides at Oxford University Hospitals Cellular Pathology division. Besides, in June 2018, procured the Irish PathXL, one of the biggest pathology picture-based examination firms. This acquisition was carried to foster incorporated tools focusing on applications in computational biology, workflow solutions, education, and image analytics.
The key players in the worldwide digital pathology market are Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan). Other conspicuous players in this market incorporate Roche (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (India), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD (China), Inspirata, Inc. (the US), Microscan Technologies (US), Proscia Inc. (US), Kanteron Systems (Spain).